🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

The sexually transmitted infection are increasing around the world, with data suggesting over 82 million new cases per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the very limited therapeutic options at this time.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in the same week. This treatment, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This milestone represents a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Outcomes and Global Access

Based on results detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The research involved hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have shared positive views. Access to a one-pill regimen such as this is seen as a "critical tool" for public health efforts. This is deemed vital to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea around the world.